Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
If a company builds assets at 18.6% a year, faster than its revenue growth rate of 16.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Medprin Regenerative Medical Technologies Co's average Total Assets Growth Rate was 3.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 2.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 18.60% per year.
During the past 8 years, Medprin Regenerative Medical Technologies Co's highest 3-Year average Total Assets Growth Rate was 52.40%. The lowest was 2.20%. And the median was 33.00%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Medprin Regenerative Medical Technologies Co's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Medprin Regenerative Medical Technologies Co Total Assets Related Terms
Medprin Regenerative Medical Technologies Co Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co Total Assets Chart
Medprin Regenerative Medical Technologies Co Annual Data
Medprin Regenerative Medical Technologies Co Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co (SZSE:301033) has a Total Assets of ¥905.0 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Medprin Regenerative Medical Technologies Co and its competitors.
Is Medprin Regenerative Medical Technologies Co's Total Assets too high?
Medprin Regenerative Medical Technologies Co's current Total Assets is ¥905.0 Mil. Overall, Medprin Regenerative Medical Technologies Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medprin Regenerative Medical Technologies Co's Total Assets compare to ABT and SYK?
Medprin Regenerative Medical Technologies Co's Total Assets of ¥905.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. Medprin Regenerative Medical Technologies Co's current Total Assets is ¥905.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medprin Regenerative Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co (SZSE:301033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥73.38, compared to a current price of ¥53.02 — trading 27.7% below its estimated fair value. The current Total Assets is ¥905.0 Mil. Medprin Regenerative Medical Technologies Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Medprin Regenerative Medical Technologies Co (SZSE:301033), the current Total Assets is ¥905.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medprin Regenerative Medical Technologies Co (SZSE:301033) Overvalued in 2026?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co stock appears to be undervalued.
The current stock price of ¥53.02 is trading 27.7% below its estimated GF Value™ of ¥73.38.
GuruFocus considers Medprin Regenerative Medical Technologies Co to be Modestly Undervalued.
Key valuation signals for SZSE:301033:
Total Assets: ¥905.0 Mil
GF Value™: ¥73.38 vs. price of ¥53.02 (27.7% below fair value)
No single metric tells the full story. See the SZSE:301033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301033 has been successfully added to your 
